Overview

Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)

Status:
Completed

Trial end date:
2020-04-24

Target enrollment:

Participant gender:

Summary

This study is an open-label Phase 1/ 2 evaluation of CB-839 in combination with nivolumab in patients with clear cell renal cell carcinoma, melanoma, and non-small cell lung cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Calithera Biosciences, Inc

Treatments:

Antibodies, Monoclonal
Nivolumab